Last Price$233.1(0.2%)
Market Cap$34.6B
LTM Total Debt to Total Equity
0.2x
5Y avg
0.4x
Medical - Instruments & Supplies industry
median
0.2x
Stock quality & Intrinsic value
8/10
(0.2%) overvalued
ResMed Inc. Total Debt to Total Equity
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Jun'05 | Jun'06 | Jun'07 | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Jun'16 | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt to Total Equity | 0.4x | 0.2x | 0.1x | 0.1x | 0.1x | 0.1x | 0.1x | 0.2x | 0.2x | 0.2x | 0.2x | 0.7x | 0.6x | 0.1x | 0.6x | 0.5x | 0.3x | 0.3x | 0.4x | 0.2x |
Overvalued or undervalued?
Check the intrinsic value for RMD
and see if it's the right time to invest.
ResMed Inc. (RMD) Total Debt to Total Equity comparison analysis
General
LTM Total Debt to Total Equity
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
ResMed Inc.RMD
0.2x
10.9%
13.4%
21.8%
Median Peer Set
0.3x
1.7%
23.0%
10.2%
Baxter International Inc.BAX
1.9x
(69.5%)
(100.0%)
(6.9%)
Masimo CorporationMASI
0.7x
0.6%
(42.5%)
4.0%
Becton, Dickinson and CompanyBDX
0.6x
4.2%
18.3%
8.4%
Repligen CorporationRGEN
0.3x
(21.1%)
(80.9%)
5.6%
The Cooper Companies, Inc.COO
0.3x
8.4%
32.2%
10.1%
AptarGroup, Inc.ATR
0.3x
2.7%
30.2%
10.5%
Alcon Inc.ALC
0.2x
8.5%
182.9%
10.3%
West Pharmaceutical Services, Inc.WST
0.1x
(1.9%)
(15.5%)
17.0%
Hologic, Inc.HOLX
0.0x
(0.0%)
81.1%
19.6%
Intuitive Surgical, Inc.ISRG
0.0x
17.2%
27.7%
27.8%
RMD key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Jun'05 | Jun'06 | Jun'07 | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Jun'16 | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 425.5 25.4% | 607.0 42.7% | 716.3 18.0% | 835.4 16.6% | 920.7 10.2% | 1,092.4 18.6% | 1,243.1 13.8% | 1,368.5 10.1% | 1,514.5 10.7% | 1,555.0 2.7% | 1,678.9 8.0% | 1,838.7 9.5% | 2,066.7 12.4% | 2,340.2 13.2% | 2,606.6 11.4% | 2,957.0 13.4% | 3,196.8 8.1% | 3,578.1 11.9% | 4,223.0 18.0% | 4,685.3 10.9% |
| Cost of Goods Sold (COGS) | 150.6 | 230.1 | 331.8 | 341.6 | 366.9 | 436.9 | 501.8 | 547.8 | 573.8 | 565.2 | 667.5 | 772.2 | 865.0 | 978.0 | 1,070.0 | 1,239.2 | 1,357.7 | 1,553.8 | 1,867.3 | 2,030.0 |
% margin | 274.9 64.6% | 376.9 62.1% | 384.5 53.7% | 493.8 59.1% | 553.8 60.1% | 655.5 60.0% | 741.3 59.6% | 820.7 60.0% | 940.7 62.1% | 989.8 63.7% | 1,011.4 60.2% | 1,066.5 58.0% | 1,201.7 58.1% | 1,362.2 58.2% | 1,536.6 59.0% | 1,717.8 58.1% | 1,839.1 57.5% | 2,024.3 56.6% | 2,355.7 55.8% | 2,655.3 56.7% |
| Operating Expenses | 167.1 | 244.5 | 294.3 | 348.4 | 360.0 | 412.1 | 473.4 | 525.3 | 585.8 | 578.4 | 596.2 | 625.2 | 745.0 | 801.9 | 900.6 | 908.7 | 926.7 | 1,024.0 | 1,203.7 | 1,335.4 |
| Research & Development Expenses (R&D) | 30.0 | 37.2 | 50.1 | 60.5 | 63.1 | 75.2 | 92.0 | 109.7 | 120.1 | 118.2 | 114.9 | 118.7 | 144.5 | 155.1 | 180.7 | 201.9 | 225.3 | 253.6 | 287.6 | 307.5 |
| Selling, General & Administrative Expenses (SG&A) | 135.7 | 200.2 | 237.3 | 278.1 | 289.9 | 328.9 | 371.2 | 401.6 | 430.8 | 450.4 | 472.6 | 482.6 | 554.0 | 600.4 | 645.0 | 676.7 | 670.4 | 739.4 | 874.0 | 917.1 |
% margin | 97.4 22.9% | 131.3 21.6% | 90.2 12.6% | 143.0 17.1% | 190.3 20.7% | 240.4 22.0% | 266.9 21.5% | 294.4 21.5% | 354.8 23.4% | 405.1 26.1% | 409.2 24.4% | 429.0 23.3% | 425.8 20.6% | 541.8 23.2% | 579.3 22.2% | 809.7 27.4% | 903.7 28.3% | 1,000.3 28.0% | 1,131.9 26.8% | 1,319.9 28.2% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 | 27.8 | 33.9 | 38.9 | 31.2 | 26.2 | 16.9 | 17.1 | 16.4 | 2.3 | 1.0 | 0.4 | 22.3 | 47.4 | 0.0 |
| Interest Expense | 0.0 | 1.3 | 1.3 | 10.1 | 10.1 | 10.1 | 1.8 | 4.8 | 6.4 | 6.1 | 5.8 | 11.2 | 28.2 | 28.4 | 36.2 | 40.4 | 24.0 | 22.3 | 47.4 | 45.7 |
| Pre-tax Income | 96.6 | 133.4 | 98.0 | 157.9 | 201.7 | 260.6 | 303.7 | 331.9 | 385.1 | 431.1 | 435.9 | 439.6 | 418.7 | 521.3 | 518.8 | 733.1 | 883.7 | 960.5 | 1,101.7 | 1,264.8 |
% effective tax rate | 31.8 33.0% | 45.2 33.9% | 31.7 32.3% | 47.6 30.1% | 55.2 27.4% | 70.5 27.1% | 76.7 25.3% | 77.1 23.2% | 78.0 20.2% | 85.8 19.9% | 83.0 19.0% | 87.2 19.8% | 76.5 18.3% | 205.7 39.5% | 114.3 22.0% | 111.4 15.2% | 409.2 46.3% | 181.0 18.8% | 204.1 18.5% | 243.8 19.3% |
% margin | 64.8 15.2% | 88.2 14.5% | 66.3 9.3% | 110.3 13.2% | 146.4 15.9% | 190.1 17.4% | 227.0 18.3% | 254.9 18.6% | 307.1 20.3% | 345.3 22.2% | 352.9 21.0% | 352.4 19.2% | 342.3 16.6% | 315.6 13.5% | 404.6 15.5% | 621.7 21.0% | 474.5 14.8% | 779.4 21.8% | 897.6 21.3% | 1,021.0 21.8% |
| EPS | 0.47 | 0.61 | 0.43 | 0.72 | 0.97 | 1.26 | 1.49 | 1.75 | 2.15 | 2.44 | 2.51 | 2.51 | 2.42 | 2.21 | 2.83 | 4.31 | 3.27 | 5.34 | 6.12 | 6.94 |
| Diluted EPS | 0.46 | 0.58 | 0.43 | 0.70 | 0.95 | 1.23 | 1.44 | 1.71 | 2.10 | 2.39 | 2.47 | 2.49 | 2.40 | 2.19 | 2.80 | 4.27 | 3.24 | 5.30 | 6.09 | 6.92 |
% margin | 136.9 32.2% | 174.0 28.7% | 90.2 12.6% | 204.8 24.5% | 190.3 20.7% | 322.2 29.5% | 374.3 30.1% | 422.6 30.9% | 469.8 31.0% | 484.9 31.2% | 482.3 28.7% | 522.7 28.4% | 568.9 27.5% | 680.2 29.1% | 705.8 27.1% | 990.4 33.5% | 1,099.2 34.4% | 1,176.6 32.9% | 1,358.8 32.2% | 1,533.5 32.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is ResMed Inc.'s Total Debt to Total Equity?
As of today, Microsoft Corp's last 12-month Total Debt to Total Equity is 0.2x, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Total Debt to Total Equity for ResMed Inc. have been 0.3x over the past three years, and 0.4x over the past five years.
2) Is ResMed Inc.'s Total Debt to Total Equity Good?
As of today, ResMed Inc.'s Total Debt to Total Equity is 0.2x, which is lower than industry median of 0.2x. It indicates that ResMed Inc.'s Total Debt to Total Equity is Good.